Browse studies

Find your next paid study

39 recruiting studies matching your filters

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)

Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. Th…

Pulmonary Arterial Hypertension

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07218029

Phase 2

A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension

Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment,…

Pulmonary Arterial Hypertension

Estimated

~$10 – $5,625

National Institutes of Health Clinical Center (CC)NCT01712620

Phase 4

An Open-label Study to Evaluate the Safety and Tolerability of LIQ861 in Participants With WHO Group 1 PAH Transitioning From Oral Selexipag to Inhaled Treprostinil

This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) wh…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$10 – $8,750

Liquidia Technologies, Inc.NCT07759804

Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences o…

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionScleroderma Associated Pulmonary Arterial Hypertension+1 more

Estimated

~$10 – $750

Vanderbilt University Medical CenterNCT01884051

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of th…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07318597

Phase 3

Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET/CT Imaging)

Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see thi…

Allogeneic Stem Cell TransplantationLung Allograft TransplantationInterstitial Lung Disease+3 more

Estimated

~$10 – $5,625

National Heart, Lung, and Blood Institute (NHLBI)NCT07613099

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adult…

Pulmonary Arterial Hypertension

Estimated

~$10 – $8,750

Insmed IncorporatedNCT07481981

Phase 1

Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH

Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background T…

Pulmonary Arterial Hypertension

Estimated

~$10 – $8,750

35Pharma IncNCT07143448

Phase 3

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)

This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IK…

Pulmonary Arterial Hypertension

Estimated

~$10 – $8,750

Inhibikase TherapeuticsNCT07365332

Observational

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Penn Pilot Low Load Resistance Exercise Training Substudy

After completion of the Baseline study visit for the main study (MUSCLE UP-PH), participants at the University of Pennsylvania location will be invited to part…

Pulmonary Arterial Hypertension

Estimated

~$10 – $6,250

University of PennsylvaniaNCT07781709

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of childre…

Coronavirus Infection (COVID-19)Pulmonary Arterial HypertensionUrinary Tract Infections in Children+22 more

Estimated

~$10 – $750

Duke UniversityNCT04278404

Observational

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approv…

Pulmonary Arterial Hypertension

Estimated

~$10 – $6,250

Vanderbilt University Medical CenterNCT05464095